Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
|Videos|September 26, 2022
What are the next steps for PSMA-PET imaging in prostate cancer?
Author(s)Urology Times staff
Advertisement
William P. Parker, MD, discusses future applications of PSMA-PET imaging in prostate cancer. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.
Advertisement
Related to this article
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Topline results from the study are anticipated in the first half of 2027.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5